tiprankstipranks
Immunic Soars on Promising Multiple Sclerosis Data
Market News

Immunic Soars on Promising Multiple Sclerosis Data

Shares of clinical-stage biopharmaceutical company Immunic (NASDAQ:IMUX) are soaring higher today after the company announced promising data from a Phase 2 study evaluating vidofludimus calcium (IMU-838) for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Long-term treatment with Immunic’s lead candidate was associated with a low rate of disability worsening over time. Further, the results compare favorably with available trial data for current MS medications.

Despite today’s price gains, Immunic shares are still down ~87% year-to-date. Moreover, short interest in the stock remains elevated at about 23.6% at present.

Read full Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles